Type
Business expansion
Country
Malta
Region
Malta; Malta; Malta
Location of affected unit(s)
Hal Far
Sector
Manufacturing
(20 - 21) Manufacture of chemicals and pharmaceuticals
21 - Manufacture of basic pharmaceutical products and pharmaceutical preparations
21.1 - Manufacture of basic pharmaceutical products

250 jobs
Number of planned job creations
Job creation
Announcement Date
6 May 2026
Employment effect (start)
1 January 2027
Foreseen end date
31 December 2029

Description

Vantive, a US-based MedTech company spun out of Baxter International, announced a €150 million investment to build new manufacturing and research facilities in Ħal Far, Malta. The project will create 250 jobs in advanced medical equipment production for dialysis and kidney disease treatments.

Construction is set to begin later in 2026, with the plant ready in 2027 and fully operational by 2029. The investment reflects Malta’s strong manufacturing reputation, strategic location, skilled workforce, and business-friendly support framework, positioning the country as a European hub for high-value advanced industries. Vantive’s focus on cutting-edge technology underscores its commitment to scientific and technological excellence in the MedTech sector.


Citation

Eurofound (2026), Vantive, Business expansion in Malta, factsheet number 300618, European Restructuring Monitor. Dublin, https://dev.eurofound.europa.eu/restructuring-events/detail/300618.